HER2+ breast cancer
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
HER2+ breast cancer
Sep 14, 2024, 09:48 |
Insight
Aleix Prat: Reveal Genomics Announces Positive Top-line Results for HER2DX in CLEOPATRA Phase III Trial
Aleix Prat, Director of Cancer Institute and Blood Disorders at Hospital Clínic de Barcelona, shared…
Jul 1, 2024, 15:23 |
Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
Jun 24, 2024, 22:47 |
Blog
Cathy Eng: Very nice review of HER2 breast cancer update by Gregory Vidal
Cathy Eng shared a post on X: . “Very nice review of HER2 breast cancer…
Jun 9, 2024, 08:43 |
Insight
Daniel Stover: Activity post-breast cancer diagnosis: Is ‘exercise’ just ‘exercise’?
Daniel Stover, Medical Oncologist and Computational Biologist at Ohio State University Comprehensive Cancer Center, shared…
May 20, 2024, 11:18 |
Drugs
Elisa Agostinetto: Our review on emerging treatments for HER2+ breast cancer
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on LinkedIn: “Now…
May 17, 2024, 13:16 |
Blog
Ciara C. O'Sullivan of Mayo Clinic, leads the Alliance A011801 trial - Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology shared on LinkedIn: “For Trial Tuesday, Ciara C. O'Sullivan,…
May 16, 2024, 14:13 |
Opinion
Paolo Tarantino: A tremendous opportunity to validate the potential of HER2DX to predict outcomes in HER2+ BC
Paolo Tarantino made the following post on X: “HER2DX to Be Validated in Pivotal ECOG-ACRIN CompassHER2…
May 15, 2024, 13:45 |
Blog
Sergio Cifuentes Canaval: Exciting insights from the MRI-guided optimization study in HER2+ breast cancer!
Sergio Cifuentes Canaval, Student Fellow at National Autonomous University of Mexico, shared a post on LinkedIn:…
May 4, 2024, 10:27 |
Insight
Paolo Tarantino: HER2 is about to change again
Paolo Tarantino shared a previous post of him on X and added: "HER2 is about…
Apr 28, 2024, 16:53 |
Blog
Paolo Tarantino: Unmissable editorial on the current status and next steps for studying and treating brain metastases in breast oncology
Paolo Tarantino shared a post by ESMO Open, on X: "Unmissable editorial on the current status…
Apr 8, 2024, 14:26 |
Drugs
Dana-Farber’s Breast Oncology Center is leading a trial for stage 1 HER2+ Breast Cancer of T-DM1 followed by SQ trastuzumab versus TH
Dana-Farber’s Breast Oncology Center posted on X: "We are leading a randomized Phase 2 trial for…
Feb 25, 2024, 20:08 |
Blog
Zainab Shinkafi-Bagudu: I never underestimate value of teamwork
Zainab Shinkafi-Bagudu shared a post on LinkedIn: “As a CEO, I never underestimate value of teamwork…
All:
12
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube